TABLE 1.

Description of control subjects and patients with liver disease

VariableValue
ControlsPatients at stage of disease (Ishak)a
1-23-56 (complete cirrhosis)Non-HCV cirrhosisjHCC + cirrhosis
Sample size1132419573487
Ageb51 ± 1150 ± 651 ± 453 ± 855 ± 856 ± 7
% NHW/AA/H/Asianc90/10/0/098/1/1/096/2/1/185/11/2/298/0/1/088/4/2/6
ALT (IU/ml)d28 ± 575 ± 771 ± 1179 ± 1985 ± 2675 ± 12
AST (IU/ml)e26 ± 373 ± 569 ± 893 ± 11108 ± 24101 ± 18
Total bilirubinf (mg/dl)0.3 ± 0.10.3 ± 0.20.3 ± 0.41.2 ± 1.31.4 ± 0.71.6 ± 1.3
% HCV genotype 1gNAk787276NA75
HCV loadh (copies/ml)01.3 ± 0.81.6 ± 11.7 ± 1.5NA1.4 ± 1.3
Serum gamma globulin (g/dl)i0.54 ± 0.10.85 ± 0.21.1 ± 0.41.3 ± 0.81.4 ± 0.81.1 ± 0.3
  • a Fibrosis staging was based on the Ishak scoring system. For this study, stage 5 or greater was considered cirrhotic.

  • b Mean age in years. P = 0.01, HCC versus fibrosis stages 1 to 6.

  • c NHW, non-Hispanic Caucasian; AA, African American; H, Hispanic. No significant differences among groups.

  • d ALT, alanine aminotransferase. P < 0.0001, fibrosis stages 1 to 6 and HCC versus controls.

  • e AST,aspartate aminotransferase. P < 0.0001, fibrosis stages 1 to 6 and HCC versus controls.

  • f P < 0.0001 for fibrosis stages 1 through 5 and all samples with fibrosis.

  • g No significant differences among groups.

  • h No significant differences among groups.

  • i P < 0.0001, fibrosis stages 1 to 6 and HCC versus controls.

  • j Non-HCV cirrhosis: 5 hepatitis B, 6 autoimmune hepatitis, 14 cryptogenic cirrhosis, and 9 alcoholic.

  • k NA, not applicable.